Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus

Inclusion Criteria: * Patients with type 2 diabetes * Patients inadequately controlled by OAD * Patients willing to sign informed consent * Selection of study participants at the discretion of the physician * Particular attention should be paid to the drug interactions that are listed within the product label Exclusion Criteria: * Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for the final visit; * Subjects who were previously enrolled in this study * Subjects with a hypersensitivity to insulin detemir or to any of the excipients. * Women who are pregnant, breastfeeding or have the intention of becoming pregnant within next 6 months